Palifermin

Uncategorized

Palifermin

What is Palifermin
?

Palifermin is a recombinant human keratinocyte growth factor (KGF) that is used to stimulate the growth and regeneration of epithelial cells, including the cells that make up the lining of the mouth and throat. It is used to treat mouth and throat injuries, including radiation-induced injuries, and to improve the healing of oral ulcers. Palifermin is also used to prevent or reduce the incidence of oral mucositis in patients undergoing radiation therapy for head and neck cancer.

Benefits of Palifermin
and Its Uses.

Palifermin is a recombinant human keratinocyte growth factor that was first approved by the US Food and Drug Administration in 2004 for the treatment of oral mucositis in patients with hematologic malignancies who were undergoing chemotherapy. Palifermin is a member of the fibroblast growth factor family and is a potent stimulator of epithelial cell proliferation and migration.

The mechanism of action of palifermin is not completely understood, but it is thought to work by binding to and activating the keratinocyte growth factor receptor on the surface of epithelial cells. This stimulates the cells to proliferate and migrate, which helps to heal mucosal lesions.

Palifermin has been shown to be effective in the treatment of oral mucositis, which is a common complication of chemotherapy. It can reduce the incidence and severity of oral mucositis, and may also improve the patient’s quality of life. Palifermin is also effective in the treatment of other muc

Side Effects and Dosage of Palifermin

Palifermin (brand name Kepivance) is a recombinant human keratinocyte growth factor indicated for the prevention of oral mucositis in patients with hematologic malignancies receiving intensive chemotherapy that includes myelosuppressive agents. Palifermin is a fibroblast growth factor that binds to and activates the receptor tyrosine kinase KIT on epithelial cells. KIT is expressed on the surface of cells in the oral mucosa.

The recommended dosage of palifermin is 60 mcg/kg/day administered as a single intravenous dose for 3 consecutive days before the start of myelosuppressive chemotherapy, on the day of chemotherapy, and on the day after chemotherapy.

Common side effects of palifermin include:

-Nausea
-Vomiting
-Diarrhea
-Stomach pain
-Headache
-Fever
-Chills
-Rash
-Itching

Category: Uncategorized
Posts created 12429

Leave a Reply

Your email address will not be published.

Related Posts

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top